ArticleMolecular biology reports2025
Role of N6-methyladenosine methylation in transverse aortic constriction-induced cardiac fibrosis: insights from MeRIP-seq analysis.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aimed to investigate the role and potential mechanisms of N6-methyladenosine (m6A) methylation in a mouse model of transverse aortic constriction (TAC)-induced cardiac fibrosis using MeRIP-seq. A TAC-induced cardiac fibrosis mouse model was established, and cardiac function and structural parameters were assessed by echocardiography four weeks post-surgery. The global m6A methylation levels in myocardial tissues were evaluated using Dot blot analysis, and the expression levels of m6A-modifying enzymes (METTL3, METTL14, ALKBH5, FTO) were detected by qPCR and Western blot. Additionally, methylated RNA immunoprecipitation sequencing (MeRIP-Seq) was performed to identify differentially methylated sites, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses to determine the biological functions and signaling pathways of m6A-methylated genes. The results showed that TAC surgery successfully induced a cardiac fibrosis model in mice, as indicated by significantly reduced EF and LVEF and increased LVIDd and LVIDs. Moreover, m6A methylation levels were elevated in myocardial tissues of TAC mice, accompanied by upregulation of METTL3 and METTL14 expressions and downregulation of ALKBH5 and FTO expression. MeRIP-seq revealed that m6A peaks were primarily enriched in the 3' UTR regions, with 1,466 differentially methylated sites identified between TAC and sham groups, including 717 hypermethylated and 749 hypomethylated sites. Functional enrichment analyses showed that these differentially methylated genes were involved in various biological processes, including signal transduction, transcriptional regulation, and ion channel activity, and were associated with pathways such as type 2 diabetes mellitus, signaling pathways regulating pluripotency of stem cells, and insulin signaling. Thus, our findings suggested that m6A methylation played a significant role in TAC-induced cardiac fibrosis by regulating key genes involved in myocardial remodeling and functional impairment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.